Virological response to initial antiretroviral regimens containing abacavir or tenofovir

UK Collaborative HIV Cohort Study, Loveleen Bansi, Caroline Sabin, Richard Gilson, Brian Gazzard, Clifford Leen, Jane Anderson, David Dunn, Teresa Hill, Martin Fisher, Jonathan Ainsworth, Deenan Pillay, Margaret Johnson, John Walsh, Chloe Orkin, Philippa Easterbrook, Mark Gompels, Andrew Phillips

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.
Original languageEnglish
Pages (from-to)710-4
Number of pages5
JournalThe Journal of Infectious Diseases
Issue number5
Publication statusPublished - 1 Sept 2009

Keywords / Materials (for Non-textual outputs)

  • Adenine
  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active
  • Dideoxynucleosides
  • Female
  • HIV Infections
  • HIV-1
  • Humans
  • Male
  • Organophosphonates
  • Treatment Failure
  • Treatment Outcome
  • Viral Load


Dive into the research topics of 'Virological response to initial antiretroviral regimens containing abacavir or tenofovir'. Together they form a unique fingerprint.

Cite this